Ellen A Arey, RN | |
33 Whiting Hill Rd, Suite 21, Brewer, ME 04412-1021 | |
(207) 973-7478 | |
(207) 973-8707 |
Full Name | Ellen A Arey |
---|---|
Gender | Female |
Speciality | Nurse Practitioner |
Experience | 11 Years |
Location | 33 Whiting Hill Rd, Brewer, Maine |
Accepts Medicare Assignments | Yes. She accepts the Medicare-approved amount; you will not be billed for any more than the Medicare deductible and coinsurance. |
Identifier | Type | State | Issuer |
---|---|---|---|
1508206822 | NPI | - | NPPES |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
363LF0000X | Nurse Practitioner - Family | CNP131038 (Maine) | Primary |
Facility Name | Location | Facility Type |
---|---|---|
Eastern Maine Medical Center | Bangor, ME | Hospital |
Northern Light Blue Hill Memorial Hospital | Blue hill, ME | Hospital |
Sebasticook Valley Health | Pittsfield, ME | Hospital |
St Joseph Hospital | Bangor, ME | Hospital |
Group Practice Name | Group PECOS PAC ID | No. of Members |
---|---|---|
Eastern Maine Medical Center | 2062315161 | 577 |
News Archive
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).
› Verified 3 days ago
Entity Name | Eastern Maine Medical Center |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1790789147 PECOS PAC ID: 2062315161 Enrollment ID: O20040128000088 |
News Archive
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).
› Verified 3 days ago
Mailing Address | Practice Location Address |
---|---|
Ellen A Arey, RN 43 Whiting Hill Rd, Suite 300, Brewer, ME 04412-1005 Ph: () - | Ellen A Arey, RN 33 Whiting Hill Rd, Suite 21, Brewer, ME 04412-1021 Ph: (207) 973-7478 |
News Archive
Princeton University researchers have observed a self-degradation response to the antidepressant Zoloft in yeast cells that could help provide new answers to lingering questions among scientists about how antidepressants work, as well as support the idea that depression is not solely linked to the neurotransmitter serotonin.
ZOLL Medical Corporation, a manufacturer of resuscitation devices and related software solutions, announced today that the first planned review of data related to patient enrollment in the CIRC (Circulation Improving Resuscitation Care) Trial by the trial Data Safety Monitoring Board (DSMB) has been completed and the trial is proceeding with patient enrollment as originally designed.
AcelRx Pharmaceuticals, Inc., a specialty pharmaceutical company focused on the development and commercialization of innovative therapies for the treatment of acute and breakthrough pain, today announced that the U.S. Food and Drug Administration (FDA) has issued a Complete Response Letter (CRL) for the Company's new drug application (NDA) for Zalviso (sufentanil sublingual tablet system).
Glide Technologies, the development company focused on solid dose formulations of therapeutics and vaccines and non-invasive diagnostics, today announced that its novel solid dose formulation of teriparatide (parathyroid hormone) achieved successful results in a pre-clinical proof-of-concept study comparing it with the currently marketed liquid product (Forteo/Forsteo).
› Verified 3 days ago
Hailey E Geoghegan, FNPC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 735 Wilson St, Brewer, ME 04412 Phone: 207-989-1567 Fax: 207-989-2286 | |
Cameron L Goller, FNPC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 735 Wilson St, Brewer, ME 04412 Phone: 207-989-1567 Fax: 207-989-2287 | |
Brooke A Morin, FNPC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 735 Wilson St, Brewer, ME 04412 Phone: 207-989-1567 Fax: 207-989-2286 | |
Amy A Langley, FNPC Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 735 Wilson Street, Brewer, ME 04412 Phone: 207-992-2601 Fax: 207-989-2280 | |
Bobbi J Mclain, CFNP Nurse Practitioner Medicare: Medicare Enrolled Practice Location: 735 Wilson St, Brewer, ME 04412 Phone: 207-404-8100 Fax: 207-947-0435 | |
Karrie Ann Ouellette, FNP-C Nurse Practitioner Medicare: Accepting Medicare Assignments Practice Location: 33 Whiting Hill Rd, Brewer, ME 04412 Phone: 207-973-7478 | |
Janice L Pilotte, FNP Nurse Practitioner Medicare: Not Enrolled in Medicare Practice Location: 33 Whiting Hill Rd, Suite 21, Brewer, ME 04412 Phone: 207-973-7478 Fax: 207-973-7807 |